Plus Therapeutics Inc. (NASDAQ:PSTV) went down by -7.34% from its latest closing price compared to the recent 1-year high of $5.42. The company’s stock price has collected -0.91% of loss in the last five trading sessions. Press Release reported 3 hours ago that Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement
Is It Worth Investing in Plus Therapeutics Inc. (NASDAQ :PSTV) Right Now?
Plus, the 36-month beta value for PSTV is at 0.37. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Plus Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $6.42. PSTV currently public float of 21.06M and currently shorts hold a 1.55% ratio of that float. Today, the average trading volume of PSTV was 970.28K shares.
PSTV’s Market Performance
PSTV stocks went down by -0.91% for the week, with a monthly drop of -21.86% and a quarterly performance of -6.84%, while its annual performance rate touched -13.15%. The volatility ratio for the week stands at 8.64% while the volatility levels for the past 30 days are set at 7.02% for Plus Therapeutics Inc.. The simple moving average for the period of the last 20 days is -13.66% for PSTV stocks with a simple moving average of -17.33% for the last 200 days.
Analysts’ Opinion of PSTV
Many brokerage firms have already submitted their reports for PSTV stocks, with Ladenburg Thalmann repeating the rating for PSTV by listing it as a “Buy.” The predicted price for PSTV in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on January 25th of the current year 2021.
Maxim Group, on the other hand, stated in their research note that they expect to see PSTV reach a price target of $6. The rating they have provided for PSTV stocks is “Buy” according to the report published on October 16th, 2020.
PSTV Trading at -18.21% from the 50-Day Moving Average
After a stumble in the market that brought PSTV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.73% of loss for the given period.
Volatility was left at 7.02%, however, over the last 30 days, the volatility rate increased by 8.64%, as shares sank -20.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.76% lower at present.
During the last 5 trading sessions, PSTV fell by -5.80%, which changed the moving average for the period of 200-days by -19.47% in comparison to the 20-day moving average, which settled at $2.31. In addition, Plus Therapeutics Inc. saw 7.92% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at PSTV starting from HEDRICK MARC H, who purchase 2,183 shares at the price of $2.28 back on Apr 30. After this action, HEDRICK MARC H now owns 18,580 shares of Plus Therapeutics Inc., valued at $4,970 using the latest closing price.
HEDRICK MARC H, the Chief Executive Officer of Plus Therapeutics Inc., purchase 2,500 shares at $2.50 during a trade that took place back on Mar 04, which means that HEDRICK MARC H is holding 16,397 shares at $6,250 based on the most recent closing price.
Stock Fundamentals for PSTV
Current profitability levels for the company are sitting at:
- -2905.28 for the present operating margin
The net margin for Plus Therapeutics Inc. stands at -2719.80. The total capital return value is set at -76.02, while invested capital returns managed to touch -307.21. Equity return is now at value -178.50, with -58.90 for asset returns.
Based on Plus Therapeutics Inc. (PSTV), the company’s capital structure generated 230.81 points at debt to equity in total, while total debt to capital is 69.77. Total debt to assets is 57.79, with long-term debt to equity ratio resting at 17.42. Finally, the long-term debt to capital ratio is 5.27.
When we switch over and look at the enterprise to sales, we see a ratio of 25.06, with the company’s debt to enterprise value settled at 0.92. The receivables turnover for the company is 0.46 and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.07.